--- title: "BridgeBio Oncology Therapeutics (BBOT) news: offering and merger" url: "https://aibio.space/companies/bridgebio-oncology-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "BBOT offering and merger news: Helix Acquisition Corp. II (now BridgeBio Oncology) keeps $120 million in trust. BridgeBio Oncology Therapeutics, Inc." --- BBOT BridgeBio Oncology Therapeutics, Inc. NASDAQ · United States # BridgeBio Oncology Therapeutics (BBOT) news BBOT offering and merger news Mergers · 2025-08-13 ## [Helix Acquisition Corp. II (now BridgeBio Oncology Therapeutics) completes business combination](https://aibio.space/news/helix-acquisition-corp-ii-now-bridgebio-oncology-therapeutics/) BridgeBio Oncology Therapeutics, the former Helix Acquisition Corp. II, closed its merger on August 11, 2025 and reports gross proceeds of approximately $381.8 million. BBOT's unaudited statements show a net loss of $50,490 thousand and $42,892 thousand used in operations for the first half of 2025. ## Latest BridgeBio Oncology Therapeutics news 1. 2025-08-06 Financings [Helix Acquisition Corp. II (now BridgeBio Oncology) keeps $120 million in trust](https://aibio.space/news/helix-acquisition-corp-ii-now-bridgebio-oncology-keeps-120-million/) Helix says about $120 million remains in trust after redemptions, and that a $261 million private placement led by Cormorant Asset Management would bring the merger with BBOT to about $382 million gross. 2. 2025-07-11 Mergers [Helix Acquisition Corp. II (now BridgeBio Oncology Therapeutics) says S-4 is effective, vote set for August 4](https://aibio.space/news/helix-acquisition-corp-ii-now-bridgebio-oncology-therapeutics-says-s-4/) The shell company says the registration statement for its merger with BBOT is effective and set a shareholder meeting for August 4, 2025, but the release gives no deal value or minimum cash figure. 3. 2025-03-11 Distress [Helix Acquisition Corp. II (now BridgeBio Oncology Therapeutics) files annual report](https://aibio.space/news/helix-acquisition-corp-ii-now-bridgebio-oncology-therapeutics-files/) The blank-check company's annual report says it must liquidate if it does not close its deal with BridgeBio Oncology by February 14, 2026, and that doubt over its ability to continue is substantial. ## BridgeBio Oncology Therapeutics at a glance - **Ticker**: BBOT - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $225.7 million ### Related companies - [Spero Therapeutics](https://aibio.space/companies/spero-therapeutics/) NASDAQ: SPRO - [Filana Therapeutics](https://aibio.space/companies/filana-therapeutics/) NASDAQ: FLNA - [Scholar Rock Holding](https://aibio.space/companies/scholar-rock/) NASDAQ: SRRK - [Conexeu Sciences](https://aibio.space/companies/conexeu-sciences/) NASDAQ: CNXU - [Life Stem Genetics](https://aibio.space/companies/life-stem-genetics/) OTC: LIFS - [Apnimed](https://aibio.space/companies/apnimed/) NASDAQ: APMD - [eFFECTOR Therapeutics](https://aibio.space/companies/effector-therapeutics/) OTC: EFTR - [Bright Minds Biosciences](https://aibio.space/companies/bright-minds-biosciences/) CSE: DRUG ### Also on NASDAQ - [GRAIL](https://aibio.space/companies/grail/) GRAL - [Lunai Bioworks](https://aibio.space/companies/lunai-bioworks/) LNAI - [Seres Therapeutics](https://aibio.space/companies/seres-therapeutics/) MCRB - [EXAGEN INC.](https://aibio.space/companies/exagen/) XGN - [CYPHERPUNK TECHNOLOGIES INC.](https://aibio.space/companies/cypherpunk-technologies/) CYPH - [Structure Therapeutics](https://aibio.space/companies/structure-therapeutics/) GPCR ## BridgeBio Oncology Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$121.2 million](https://www.sec.gov/Archives/edgar/data/1869105/000119312526094112/) | [$73.1 million](https://www.sec.gov/Archives/edgar/data/1869105/000119312526094112/) | | Net income (loss) | [-$134.0 million](https://www.sec.gov/Archives/edgar/data/1869105/000119312526094112/) | [-$74.3 million](https://www.sec.gov/Archives/edgar/data/1869105/000119312526094112/) | | Cash from operations | [-$113.9 million](https://www.sec.gov/Archives/edgar/data/1869105/000119312526094112/) | [-$55.0 million](https://www.sec.gov/Archives/edgar/data/1869105/000119312526094112/) | | Cash and equivalents | [$373.7 million](https://www.sec.gov/Archives/edgar/data/1869105/000119312526344661/) | [$30.9 million](https://www.sec.gov/Archives/edgar/data/1869105/000119312526094112/) | | Short-term investments | [$51.8 million](https://www.sec.gov/Archives/edgar/data/1869105/000119312526344661/) | [$124.8 million](https://www.sec.gov/Archives/edgar/data/1869105/000119312526094112/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $54.1 million, plus short-term investments of $171.6 million, $225.7 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about BridgeBio Oncology Therapeutics Has BridgeBio Oncology Therapeutics raised money recently? Our latest story on this, dated Aug 6, 2025: "Helix Acquisition Corp. II (now BridgeBio Oncology) keeps $120 million in trust". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/helix-acquisition-corp-ii-now-bridgebio-oncology-keeps-120-million/). Is BridgeBio Oncology Therapeutics involved in a merger or acquisition? Our latest story on this, dated Aug 13, 2025: "Helix Acquisition Corp. II (now BridgeBio Oncology Therapeutics) completes business combination". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/helix-acquisition-corp-ii-now-bridgebio-oncology-therapeutics/). What is the ticker symbol of BridgeBio Oncology Therapeutics? BridgeBio Oncology Therapeutics, Inc. trades under the ticker BBOT on NASDAQ. Where is BridgeBio Oncology Therapeutics listed? BridgeBio Oncology Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: BIVA:BBOT; BMV:BBOT. What is the SEC CIK of BridgeBio Oncology Therapeutics? The SEC Central Index Key (CIK) for BridgeBio Oncology Therapeutics, Inc. is 1869105. Its filings are on SEC EDGAR. How many shares does BridgeBio Oncology Therapeutics have outstanding? 80,174,267 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-11. Which country or territory is BridgeBio Oncology Therapeutics listed under? Our directory records BridgeBio Oncology Therapeutics, Inc. under United States. What does BridgeBio Oncology Therapeutics do? Our directory classifies BridgeBio Oncology Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of BridgeBio Oncology Therapeutics? The ISIN recorded for BridgeBio Oncology Therapeutics, Inc. is US1079241022. Does aibio.space cover BridgeBio Oncology Therapeutics? aibio.space lists BridgeBio Oncology Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is BridgeBio Oncology Therapeutics incorporated? SEC records list its state or country of incorporation as DE. Is BridgeBio Oncology Therapeutics profitable? BridgeBio Oncology Therapeutics, Inc. reported a net loss of $134.0 million for the fiscal year ended Dec 31, 2025, and used $113.9 million of cash in operations, per its annual report to the SEC. How much does BridgeBio Oncology Therapeutics spend on research and development? $121.2 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does BridgeBio Oncology Therapeutics have? $225.7 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest BridgeBio Oncology Therapeutics (BBOT) stock news? Our latest story on BridgeBio Oncology Therapeutics, dated Aug 13, 2025: "Helix Acquisition Corp. II (now BridgeBio Oncology Therapeutics) completes business combination". BridgeBio Oncology Therapeutics, the former Helix Acquisition Corp. II, closed its merger on August 11, 2025 and reports gross proceeds of approximately $381.8 million. BBOT's unaudited statements show a net loss of $50,490 thousand and $42,892 thousand used in operations for the first half of 2025. [Source](https://aibio.space/news/helix-acquisition-corp-ii-now-bridgebio-oncology-therapeutics/). ## Investor discussion: BridgeBio Oncology Therapeutics Members talk about BridgeBio Oncology Therapeutics (BBOT). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at BridgeBio Oncology Therapeutics, newest first. Each line links the filing it comes from. 1. 2025-08-29 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1869105/000119312525192760/d67813ds1.htm) 2. 2025-08-13 Legal Reported a change of independent auditor. SEC Form 8-K (Items 1.01,2.01,3.02,3.03,4.01,5.01,5.02,5.03,5.05,5.06,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1869105/000121390025075190/ea025066201ex99-1_bridge.htm) 3. 2025-08-06 Financings Reported a financing. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1869105/000121390025072312/ea025199401ex99-1_helix2.htm) 4. 2025-07-11 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1869105/000121390025062955/ea024865501ex99-1_helix2.htm) 5. 2025-07-10 Financings Filed a final prospectus for a securities offering. SEC Form 424B4. [Source](https://www.sec.gov/Archives/edgar/data/1869105/000121390025062864/ea0237401-11.htm) 6. 2025-03-11 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1869105/000121390025022387/ea0233379-10k_helix2.htm) 7. 2025-02-28 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1869105/000121390025018334/ea023255501ex99-1_helix2.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:BBOT on TradingView](https://www.tradingview.com/symbols/NASDAQ-BBOT/). ## SEC filings and registration - **SEC name**: BridgeBio Oncology Therapeutics, Inc. - **CIK**: 1869105 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: BBOT (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 256 E. GRAND AVENUE, SUITE 104, SOUTH SAN FRANCISCO, CA, 94080 - **Phone**: 857 702 0377 - **Shares outstanding**: 80,174,267 as of 2026-08-06 (10-Q filed 2026-08-11) - **Former names**: Helix Acquisition Corp. II ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1869105/000119312526385225/d97546d8k.htm) filed 2026-09-08 - [S-3](https://www.sec.gov/Archives/edgar/data/1869105/000119312526378637/d140634ds3.htm) filed 2026-09-01 - [10-Q](https://www.sec.gov/Archives/edgar/data/1869105/000119312526344661/bbot-20260630.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1869105/000119312526344608/bbot-20260811.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1869105/000119312526277513/d137002d8k.htm) filed 2026-06-22 - [10-Q](https://www.sec.gov/Archives/edgar/data/1869105/000119312526219829/bbot-20260331.htm) filed 2026-05-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1869105/000119312526219801/bbot-20260512.htm) filed 2026-05-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1869105/000119312526191512/d68319d8k.htm) filed 2026-04-29 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001869105), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details BridgeBio Oncology Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker BBOT, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: BridgeBio Oncology Therapeutics, Inc. - **Ticker**: BBOT - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US1079241022 - **Other listed symbols**: BIVA:BBOT; BMV:BBOT - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-BBOT/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/bridgebio-oncology-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "BridgeBio Oncology Therapeutics (BBOT) news: offering and merger", 2026-10-31, https://aibio.space/companies/bridgebio-oncology-therapeutics/